Rajeev Kandukuri, MD
Psychiatry · Parker, CONPI 1770704025
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,114 and has fallen 63.6% since, to $405 in 2024. Among psychiatry clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$682
- Neurocrine Biosciences, Inc.$653
- Acadia Pharmaceuticals Inc$487
- Alkermes, Inc.$464
- Sunovion Pharmaceuticals Inc.$363
- Teva Pharmaceuticals USA, Inc.$297
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,45996%
- Education$1714%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $682 |
| Neurocrine Biosciences, Inc. | 42 | $653 |
| Acadia Pharmaceuticals Inc | 23 | $487 |
| Alkermes, Inc. | 21 | $464 |
| Sunovion Pharmaceuticals Inc. | 33 | $363 |
| Teva Pharmaceuticals USA, Inc. | 9 | $297 |
| Lundbeck LLC | 14 | $260 |
| Otsuka America Pharmaceutical, Inc. | 12 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $234 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $199 |
| Johnson & Johnson | 9 | $142 |
| Idorsia Pharmaceuticals US Inc | 7 | $110 |
| Indivior Inc. | 5 | $101 |
| Eisai Inc. | 5 | $79 |
| Vanda Pharmaceuticals Inc. | 4 | $71 |
| Noven Therapeutics, LLC | 3 | $57 |
| Avanir Pharmaceuticals, Inc. | 3 | $46 |
| Merck | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Corium, LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $13 |
| MDD US Operations, LLC | 1 | $11 |
How this compares
$4,630 in reported general payments places this provider in the 90th percentile of 559 psychiatry providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $94,313 |
| TrintellixVortioxetine Hydrobromide | 22 | $26,272 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 80 | $18,398 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 42 | $3,898 |
| EliquisApixaban | 12 | $2,969 |
| Vilazodone Hcl | 11 | $2,754 |
| Divalproex Sodium | 18 | $2,715 |
| Clozapine | 38 | $2,635 |
| Paliperidone ErPaliperidone | 12 | $2,058 |
| Quetiapine Fumarate | 88 | $1,781 |
| Duloxetine Hcl | 51 | $1,167 |
| Bupropion XlBupropion Hcl | 39 | $1,164 |
| Hydroxyzine Hcl | 54 | $1,130 |
| Gabapentin | 41 | $1,011 |
| Bupropion Hcl SrBupropion Hcl | 19 | $766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $653 | $94,31312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $234 | $26,27222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 559 psychiatry providers in Colorado.
Other psychiatry in Parker
- Miani GironParker$2K
- John HardyPueblo$828K
- Larry SandersLittleton$760K
- Jeffrey RichmondDenver$424K
- Jennifer FrenchGlendale$115K
- Charles ParkLone Tree$89K
- Cynthia EppersonAurora$64K
- Brian WiseCentennial$44K
- Robert CowanCentennial$29K
- Brenda CzabanDenver$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.